Prior to joining Stentys, Piot served at Banque Worms in Hong Kong in 1994 as a financial analyst before entering into corporate finance teams at Credit Lyonnais Hong Kong Branch.

He joined the Equity Capital Market (ECM) team at Credit Lyonnais in Paris as project manager in 1997, Oddo & Cie in 2000 and then went to Natixis as part of the ECM team.

Piot also served as a CFO of French biotech Ipsogen that develops and commercialises molecular diagnostic tools.

Stentys claimed that its stents are self-apposing stents that offer a safer treatment option for patients by adapting exactly to the changes in diameter of the coronary arteries during the post-AMI phase.